What is BPC-157?
BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protective protein found naturally in human gastric juice. The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1,419 Daltons.
Unlike many peptides used in research, BPC-157 demonstrates notable stability in acidic environments — a property attributed to its gastric juice origins. This characteristic has attracted sustained attention from gastrointestinal researchers.
| Full Name | Body Protection Compound-157 |
| Type | Synthetic Pentadecapeptide |
| Amino Acids | 15 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) |
| Molecular Weight | ~1,419 Da |
| Origin | Derived from human gastric juice protein |
| Stability | Stable in acidic environments (pH 2–4) |
| Form | Lyophilized powder (research grade) |
Key research areas
Gastrointestinal research
The most extensively studied application of BPC-157 involves gastrointestinal tissue. Research in animal models suggests that BPC-157 may influence the healing of various gastrointestinal lesions, including those induced by NSAIDs, alcohol, and other damaging agents. Studies indicate potential cytoprotective properties, with researchers observing effects on mucosal integrity and blood vessel formation in gastric tissue.
Musculoskeletal research
A growing body of preclinical research has examined BPC-157’s potential effects on tendons, ligaments, muscles, and bones. Animal studies suggest it may promote tendon-to-bone healing and influence the recovery of transected tendons. Researchers have noted apparent effects on fibroblast activity and collagen organization in these models.
Wound healing and angiogenesis
Several research groups have investigated BPC-157’s relationship with angiogenesis — the formation of new blood vessels. Preclinical studies suggest it may promote the VEGF (vascular endothelial growth factor) pathway, which plays a central role in tissue repair and vascularization. Hsieh et al. (Journal of Molecular Medicine, 2017) documented the VEGFR2 activation mechanism specifically.
Neuroprotective research
Emerging preclinical research has explored BPC-157’s potential interactions with the nervous system. Some animal studies suggest possible effects on dopaminergic and serotonergic systems, though this area remains in early stages. Researchers have also examined its potential in models of peripheral nerve damage. Vukojevic et al. (Neural Regeneration Research, 2022) provides a useful review of the CNS-related findings.
Nitric oxide system interactions
Research indicates that BPC-157 may interact with the nitric oxide (NO) system, which plays roles in vasodilation, immune response, and neurotransmission. Understanding these interactions is an active area of peptide research.
Research methodology considerations
When working with BPC-157 in research settings, several factors matter. Research-grade BPC-157 should have ≥99% purity verified by HPLC, with mass spectrometry confirmation of molecular identity. Researchers typically reconstitute lyophilized BPC-157 in bacteriostatic water, calculating precise concentrations based on vial content and solvent volume. In animal research, BPC-157 has been studied via subcutaneous, intraperitoneal, intragastric, and topical routes. Published preclinical studies have used a range from 1 µg/kg to 50 µg/kg in animal models, depending on the research question. Proper experimental design requires vehicle controls and, where possible, positive controls.
Storage and handling
Proper storage protocol
Lyophilized (powder form): Store at -20°C for optimal long-term stability. BPC-157 is relatively stable but benefits from cold storage to prevent degradation over months.
Reconstituted (liquid form): Store at 2–8°C (standard refrigeration) and use within 2–4 weeks. Use bacteriostatic water as the reconstitution solvent for its preservative properties.
Protect from light: UV exposure accelerates peptide degradation. Store in amber vials or wrap in foil.
Current state of research
While BPC-157 has been the subject of numerous preclinical studies, the majority of published research has been conducted in animal models. Human clinical trials remain limited. The peptide continues to be a subject of active scientific investigation, and researchers should consult the latest peer-reviewed literature for the most current findings.
BPC-157 is part of a wider push to study naturally derived peptides and their biological activities. As analytical methods improve and more researchers contribute to the field, the mechanistic picture is still developing — particularly in the neurological and cardiovascular areas.
Research use disclaimer
BPC-157 is sold strictly for in vitro and in vivo research purposes only. It is not intended for human consumption, therapeutic use, or self-administration. All information presented here is for educational and research reference purposes. Researchers should comply with all applicable regulations and institutional review requirements. CertaPeptides does not make any claims regarding therapeutic efficacy in humans.
Recent BPC-157 research: neurological and cardiovascular findings
Recent years have seen BPC-157 research expand into areas beyond its established gastrointestinal and musculoskeletal applications. The neurological findings are worth noting for researchers working in those adjacent areas.
Neuroinflammation and nervous system recovery
Preclinical studies have investigated BPC-157’s effects on glial cell behavior following neural injury. The primary observations concern microglial polarization — specifically a shift from pro-inflammatory M1 phenotype toward M2 phenotype, which is associated with tissue repair and neurogenesis support. Researchers have also documented effects on blood-brain barrier integrity in injury models, with improvements in tight junction stability and reduced inflammatory infiltration. Whether these effects translate beyond rodent models remains an open question.
Vukojevic et al. (Neural Regeneration Research, 2022) covers the CNS mechanisms in detail if this area is relevant to your research program. The data is preclinical, but the consistency across different injury models is notable.
Cardiovascular and endothelial effects
A separate body of work has examined BPC-157 in cardiovascular models. Studies have reported improvements in vascular endothelial function, nitric oxide production, and vasodilation in preclinical settings. There’s also been interest in post-ischemic recovery — cardiac and cerebral tissue recovery following ischemic injury — though this work is still primarily in animal models. The anticoagulant properties observed in some studies are interesting but need further characterization in terms of dose-response and mechanism.
Metabolic observations
Some preclinical work has examined BPC-157’s effects on insulin signaling, mitochondrial function, and lipid profiles in metabolic syndrome models. The data is early and the sample sizes are small. There is speculative interest in potential complementarity with GLP-1 receptor agonists given some mechanistic overlap in metabolic pathways, but this hasn’t been studied directly in controlled research settings.
Combination protocols in research
Researchers have increasingly examined BPC-157 in combination with other peptides, drawing on their complementary mechanisms. The BPC-157 + TB-500 pairing is the most studied — BPC-157’s angiogenic signaling and TB-500’s cell migration promotion address different phases of the repair cascade. For research on connective tissue remodeling, some groups have added GHK-Cu given its collagen maturation effects. For context on comparing these compounds, see our BPC-157 vs TB-500 comparison guide.
Research protocol considerations (updated)
Published animal research has most commonly used subcutaneous injection as the primary route, with doses in the range of 1–50 µg/kg depending on the model and endpoint. Some studies have used twice-daily dosing for shorter protocols; others have used once-daily for longer-duration experiments. The dose-response relationship varies meaningfully by tissue target, so researchers should anchor to the specific literature for their model rather than assuming dose universality across applications.
FAQ
Can BPC-157 be studied alongside semaglutide or tirzepatide?
There is some preclinical interest in this combination based on overlapping metabolic pathway involvement — both improve vascular function and have anti-inflammatory properties in their respective models. Direct controlled studies of this combination are limited. It remains an active research area rather than an established protocol.
What are BPC-157’s effects on muscle tissue specifically?
BPC-157 is not a direct anabolic agent. The evidence points to indirect effects: improved blood flow to injured tissue, reduced local inflammation, and in some models, promotion of satellite cell (muscle stem cell) proliferation. Enhanced collagen organization in muscle fasciae has also been reported. These effects create conditions that may support recovery and adaptation, but should not be conflated with direct anabolic activity.
Is BPC-157 relevant to research with older animal models?
There is some preclinical evidence suggesting BPC-157 may restore or partially compensate for age-related declines in angiogenic response and stem cell proliferation. Mitochondrial function effects are also of interest in aging contexts. Human data in elderly populations is essentially absent, so claims about aging applications should be framed cautiously and anchored to the animal model literature.
References
- Sikiric P, et al. (2014). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 20(7), 1023-1035. PMID: 23701538.
- Sikiric P, et al. (2006). Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model. Life Sciences, 79(5), 483-489. PMID: 16516235.
- Seiwerth S, et al. (2014). BPC 157 effect on healing. Journal of Physiology – Paris, 108(2-3), 94-109. PMID: 24075973.
- Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research, 21(6), 976-983. PMID: 14554208.
- Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333. PMID: 27866220.
- Sikiric P, et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Gastrointestinal and Brain Effects. Current Neuropharmacology, 16(8), 1116-1145. PMID: 29651949.
- Vukojevic J, et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482-487. PMID: 34380875.
- Sikiric P, et al. (2023). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 14, 1128548. PMID: 37007028.